Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real‐world cohort of patients with lower‐risk MDS

The acquisition of subsequent genetic lesions (clonal evolution, CE) and/or the expansion of existing clones (CEXP) contributes to clonal dynamics (CD) in myelodysplastic syndromes (MDS). Although CD plays an important role in high-risk patients in disease progression and transformation into acute myeloid leukemia (AML), knowledge about CD in lower-risk MDS (LR-MDS) patients is limited due to lack of robust longitudinal data considering the long clinically stable courses of the disease. In this retrospective analysis, we delineate the frequency and the prognostic impact of CD in an unselected real-world cohort of LR-MDS patients. We screened 68 patients with a median follow-up of 40.5 months and a median of 7.5 (range: 2-22) timepoints for CE and CEXP detected by chromosomal banding analysis, fluorescence in situ hybridization, sequencing, and molecular karyotyping. In 30/68 patients, 47 CE events and a CD rate of 1 event per 4 years were documented. Of note, patients with at least 1 CE event had an increased probability for subsequent treatment. Unexpectedly, CE did not correlate with inferior outcomes, which could be reasonably explained by CD detection triggering the subsequent start of a disease-modifying therapy.

Authors

Institutions

Publication Details

Journal
HemaSphere
Published
2024-09-01
DOI
https://doi.org/10.1002/hem3.70014
Citations
2
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.91

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real‐world cohort of patients with lower‐risk MDS

Katayoon Shirneshan, Catharina Müller‐Thomas, Julie Schanz, Elżbieta Brzuszkiewicz et al.
2 citations
HemaSphere
Acute Myeloid Leukemia Research
0.91
article

Comprehensive sequential genetic analysis delineating frequency, patterns, and prognostic impact of genomic dynamics in a real‐world cohort of patients with lower‐risk MDS

Katayoon Shirneshan, Catharina Müller‐Thomas, Julie Schanz, Elżbieta Brzuszkiewicz, Hannes Treiber, Paolo Mazzeo, Katharina Rittscher, Ekaterina Balaian, John Wiedenhöft, Katharina S. S. Götze, Katja Sockel, Doris Steinemann, Uwe Platzbecker, Christina Ganster, Friederike Braulke, Maximilian Schieck, Detlef Haase, Ulrich Germing
article en
2 citations

Abstract

The acquisition of subsequent genetic lesions (clonal evolution, CE) and/or the expansion of existing clones (CEXP) contributes to clonal dynamics (CD) in myelodysplastic syndromes (MDS). Although CD plays an important role in high-risk patients in disease progression and transformation into acute myeloid leukemia (AML), knowledge about CD in lower-risk MDS (LR-MDS) patients is limited due to lack of robust longitudinal data considering the long clinically stable courses of the disease. In this retrospective analysis, we delineate the frequency and the prognostic impact of CD in an unselected real-world cohort of LR-MDS patients. We screened 68 patients with a median follow-up of 40.5 months and a median of 7.5 (range: 2-22) timepoints for CE and CEXP detected by chromosomal banding analysis, fluorescence in situ hybridization, sequencing, and molecular karyotyping. In 30/68 patients, 47 CE events and a CD rate of 1 event per 4 years were documented. Of note, patients with at least 1 CE event had an increased probability for subsequent treatment. Unexpectedly, CE did not correlate with inferior outcomes, which could be reasonably explained by CD detection triggering the subsequent start of a disease-modifying therapy.

HemaSphereVol. 8(9)
Medizinische Hochschule Hannover (DE), Universitätsmedizin Göttingen (DE), University Hospital Leipzig (DE), University Hospital Carl Gustav Carus (DE), Heinrich Heine University Düsseldorf (DE), Technical University of Munich (DE), Leipzig University (DE)
Bristol-Myers Squibb
Openalex Percentile: Top 23%
Acute Myeloid Leukemia Research
0.91
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.